⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 1, 2025

Supplemental Figure 3 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer

Rosa A. van Amerongen Sander Tuit Dennis F.G. Remst Anne K. Wouters Sterre L. Siekman Renate S. Hagedoorn Dirk M. van der Steen Michel G.D. Kester Arnoud H. de Ru Geertje van der Horst Masashi Matsuda Fumihiko Ishikawa Peter A. van Veelen J.H. Frederik Falkenburg Mirjam H.M. Heemskerk

View at Publisher

Ask AI

Bookmark

Share

Key Points

MAIN FINDING: TCR-based therapy targeting kallikrein-related peptidase 4 is safe and shows effectiveness against prostate cancer.
KEY EVIDENCE: Mass spectra analysis revealed distinct peptide presentations in HLA types linked to KLK4.
APPROACH: The study employed tandem mass spectrometry to compare eluted peptides from prostate cancer samples and synthetic origins.
SIGNIFICANCE: This therapy offers a potential new way to treat prostate cancer, relying on immune response mechanisms.

Implication

TCR-based therapy reduces prostate cancer cells using KLK4 peptides, suggesting a promising treatment avenue.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Amerongen et al. (2025) studied this question.

synapsesocial.com/papers/689a0c72e6551bb0af8d02b2 https://doi.org/10.1158/2326-6066.29759687

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplemental Figure 7 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer2025
2Data from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer2025
3Supplemental Figure 6 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer2025
4Supplemental Figure 2 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer2025
5Supplemental Figure 5 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer2025

Supplemental Figure 1 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer2025
Supplemental Figure 4 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer2025
Supplemental Figure 8 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer2025